Vera Therapeutics
VERA
70 hedge funds and large institutions have $290M invested in Vera Therapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 10 closing their positions.
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
19% more funds holding
Funds holding: 59 → 70 (+11)
11.94% more ownership
Funds ownership: 77.12% → 89.07% (+12%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less capital invested
Capital invested by funds: $413M → $290M (-$123M)
41% less call options, than puts
Call options by funds: $185K | Put options by funds: $314K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$22.8M |
| 2 |
CC
Commodore Capital
New York
|
+$21.8M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$15.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.38M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.75M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.51M |
| 4 |
Walleye Capital
New York
|
-$1.69M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$880K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Walleye Trading
New York
| – | -$212K | -10,945 | Closed |
|
|
CS
77
Credit Suisse
Zurich,
Switzerland
| – | -$185K | -9,558 | Closed |
|
|
GTCM
78
Gyon Technologies Capital Management
Denville,
New Jersey
| – | -$182K | -9,413 | Closed |
|
79
Citigroup
New York
| – | -$9.04K | -467 | Closed |
|
80
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$46 | -6 | -35% |
|
VERA Hedge Fund Activity: Q1 2023 in Review
70 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q1 2023, worth a combined $290M — down 30% from $413M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VERA positions and 10 closed out — a net gain of 12 holders — while 29 added to existing stakes and 10 trimmed.
The largest buyer was Carlyle Group, opening a new position worth an estimated $22.8M. The largest seller was Citadel Advisors, cutting an estimated $9.38M.
- 70 institutional investors held Vera Therapeutics (VERA) as of Q1 2023, up from 59 in Q4 2022.
- Funds reported $290M of Vera Therapeutics stock for Q1 2023, down 30% quarter-over-quarter.
- 22 funds opened new Vera Therapeutics positions in Q1 2023 and 10 closed out, a net change of +12 holders.
- The largest Vera Therapeutics buyer in Q1 2023 was Carlyle Group, an estimated $22.8M added.
- The largest Vera Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $9.38M sold.
Based on aggregated 13F filings for Q1 2023.